0000000000329917

AUTHOR

C. Carrera

showing 4 related works from this author

Examining the generalizability of research findings from archival data

2022

This research project benefitted from Ministry of Education (Singapore) Tier 1 Grant R-313-000-131-115 (to A. Delios), National Science Foundation of China Grants 72002158 (to H.T.) and 71810107002 (to H.T.), grants from the Knut and Alice Wallenberg Foundation (to A. Dreber) and the Marianne and Marcus Wallenberg Foundation (through a Wallenberg Scholar grant; to A. Dreber), Austrian Science Fund (FWF) Grant SFB F63 (to A. Dreber), grants from the Jan Wallander and Tom Hedelius Foundation (Svenska Handelsbankens Forskningsstiftelser; to A. Dreber), and an Research & Development (R&D) research grant from Institut Européen d'Administration des Affaires (INSEAD) (to E.L.U.). Dmitrii Dubrov, o…

research reliabilityMultidisciplinaryZA4050 Electronic information resourcesDASVDP::Matematikk og Naturvitenskap: 400M-PSI/06 - PSICOLOGIA DEL LAVORO E DELLE ORGANIZZAZIONIarchival data; context sensitivity; generalizability; reproducibility; research reliabilityResearch reliability generalizability archival data reproducibility context sensitivity:Ciências Sociais::Economia e Gestão [Domínio/Área Científica]archival dataZA4050Inequality cohesion and modernizationM-PSI/03 - PSICOMETRIAVDP::Medisinske Fag: 700Ongelijkheid cohesie en moderniseringcontext sensitivitygeneralizabilityreproducibilityWork Health and Performance
researchProduct

A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudin…

2021

AbstractBackgroundPsoriasis is a chronic immune-mediated inflammatory skin disease which can also involve joints. It is often associated with burdensome comorbidities which negatively impact prognosis and quality of life (QoL). Biologic agents have been shown to be effective in controlling disease progression, but their use is associated with higher costs compared with traditional systemic treatments. The economic analysis of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: an obserVAtional longitudinal study of real-life clinical practice) study aims to assess the costs and cost-effectiveness of biologics in a real-world context in Italy.MethodsThe annualised…

Response ratemedicine.medical_specialtyCost per responderBiologicCostIxekizumabLongitudinal StudieContext (language use)Secukinumab.Severity of Illness IndexAntibodiesIndirect costsSettore MED/35Quality of lifeInternal medicinePsoriasisUstekinumabMonoclonalAdalimumab; Ixekizumab; Antibodies Monoclonal; Longitudinal Studies; Quality of Life; Psoriasis; Treatment Outcome; Severity of Illness Index; Italy; Humans; Biological Therapy; Ustekinumab; Secukinumab; Response rate; Real-world; Ixekizumab; Cost per responder; BiologicmedicineAdalimumabHumansPsoriasisLongitudinal Studieshealth care economics and organizationsSecukinumabPsoriasiAdalimumab; Biologic; Cost per responder; Costs; Ixekizumab; Real-world; Response rate; Secukinumab; Ustekinumab; Antibodies Monoclonal; Biological Therapy; Humans; Italy; Longitudinal Studies; Severity of Illness Index; Treatment Outcome; Psoriasis; Quality of Lifebusiness.industryHealth PolicyResearchAdalimumabAntibodies Monoclonalmedicine.diseaseCostsBiological TherapyIxekizumabTreatment OutcomeReal-worldItalyQuality of LifeSecukinumabUstekinumabPublic aspects of medicineRA1-1270Settore MED/35 - MALATTIE CUTANEE E VENEREEbusinessHumanmedicine.drugBMC Health Services Research
researchProduct

Pruritus characteristics in a large Italian cohort of psoriatic patients

2019

Background: Psoriasis (Ps) is a chronic systemic autoimmune disease associated with pruritus in 64–98% of patients. However, few modestly sized studies assess factors associated with psoriatic pruritus. Objective: To investigate factors associated with Ps pruritus intensity. Methods: Psoriasis patients 18 years or older seen in one of 155 centres in Italy between September 2005 and 2009 were identified from the Italian PsoCare registry. Patients without cutaneous psoriasis and those with missed information on pruritus were excluded. Results: We identified 10 802 patients, with a mean age 48.8 ± 14.3 years. Mild itch was present in 33.2% of patients, moderate in 34.4%, severe in 18.7% and ve…

MaleCross-sectional studySeverity of Illness IndexCohort Studies030207 dermatology & venereal diseases0302 clinical medicineRisk Factorseducation; itch; pruritus; psoriasis; pustular psoriasis; treatment; Adolescent; Adult; Cohort Studies; Cross-Sectional Studies; Educational Status; Facial Dermatoses; Female; Foot Dermatoses; Genitalia; Hand Dermatoses; Humans; Italy; Male; Middle Aged; Pruritus; Psoriasis; Registries; Risk Factors; Severity of Illness Index; Sex Factors; Young AdultEpidemiologyitchRegistriesYoung adultskin and connective tissue diseaseseducationtreatmentMiddle AgedSettore MED/33 - MALATTIE APPARATO LOCOMOTOREInfectious Diseasespustular psoriasisItaly030220 oncology & carcinogenesisCohortEducational StatusPRURITIS EPIDEMIOLOGYFemaleSettore MED/35 - MALATTIE CUTANEE E VENEREECohort studyAdultmedicine.medical_specialtyAdolescentPSORIASDermatologyHand DermatosesArticle03 medical and health sciencesYoung AdultPharmacotherapySex FactorsSettore MED/35PsoriasisSeverity of illnessmedicineHumansPsoriasisGenitaliaFoot Dermatosesbusiness.industryPruritusmedicine.diseaseDermatologyPruritusItch sensationCross-Sectional StudiesbusinessFacial Dermatoses
researchProduct

Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry

2014

Background: Some studies have shown that switching patients from one tumor necrosis factor (TNF)-alfa inhibitor to another may be beneficial when they have an inadequate response or an adverse event. Objective: We sought to assess the variables predicting the efficacy of the second TNF-alfa inhibitor in patients discontinuing the first TNF-alfa inhibitor. Methods: Data from all 5423 consecutive patients starting TNF-alfa inhibitor therapy for psoriasis between September 2005 and September 2010 who were included in the Italian Psocare registry were analyzed. Results: In 105 patients who switched to a second TNF-alfa inhibitor who had complete follow-up data, 75% improvement in the Psoriasis …

Maleprimary inefficacy75% improvement in the Psoriasis Area Severity Index score; PASI; PASI 75; Psoriasis Area Severity Index; TNF; biologics; efficacy; primary inefficacy; psoriasis; secondary loss of efficacy; switching; tumor necrosis factor; tumor necrosis factor-alfa inhibitors; Adult; Analysis of Variance; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Cohort Studies; Confidence Intervals; Dose-Response Relationship Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Immunoglobulin G; Italy; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Proportional Hazards Models; Psoriasis; Receptors Tumor Necrosis Factor; Registries; Retrospective Studies; Risk Assessment; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha; Young AdultSWITHCESefficacyTNFpsoriasis; psoriasis arthritis; pharmachological treatmentPASI 75Severity of Illness IndexReceptors Tumor Necrosis FactorEtanerceptCohort StudiesMonoclonalReceptorsSettore MED/35 - Malattie Cutanee E VenereeRegistriesHumanizedtumor necrosis factor-alfa inhibitors.switchingHazard ratioAntibodies MonoclonalMiddle AgedTreatment OutcomeItalyPredictive value of tests75% improvement in the Psoriasis Area Severity Index scoreFemaleDrugPsoriasis Area Severity IndexbiologicTNF-alphaAdultmedicine.medical_specialtytumor necrosis factorDermatology75% improvement in the Psoriasis Area Severity Index score; PASI; PASI 75; Psoriasis Area Severity Index; TNF; biologics; efficacy; primary inefficacy; psoriasis; secondary loss of efficacy; switching; tumor necrosis factor; tumor necrosis factor-alfa inhibitorsAntibodies Monoclonal Humanizedsecondary loss of efficacyRisk AssessmentAntibodiestumor necrosis factor-alfa inhibitorsDrug Administration ScheduleDose-Response RelationshipYoung AdultSettore MED/35Predictive Value of TestsInternal medicinePsoriasisSeverity of illnessmedicineConfidence IntervalsHumansPsoriasisbiologicsAdverse effectPsoriasis; TNF-alphaProportional Hazards ModelsRetrospective Studiespsoriasibiologics; efficacy; primary inefficacy; psoriasis; secondary loss of efficacy; switching; tumor necrosis factor-alfa inhibitors; Adalimumab; Adult; Analysis of Variance; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Cohort Studies; Confidence Intervals; Dose-Response Relationship Drug; Drug Administration Schedule; Etanercept; Female; Follow-Up Studies; Humans; Immunoglobulin G; Infliximab; Italy; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Proportional Hazards Models; Psoriasis; Receptors Tumor Necrosis Factor; Registries; Retrospective Studies; Risk Assessment; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha; Young Adult; 2708Analysis of Variancepharmachological treatmentDose-Response Relationship DrugProportional hazards modelbusiness.industrytumor necrosis factor-alfa inhibitorTumor Necrosis Factor-alphaPASIAdalimumabRetrospective cohort studypsoriasis arthritismedicine.diseaseConfidence intervalInfliximabSurgeryImmunoglobulin GMultivariate AnalysisANTI-TNFAbusiness2708Follow-Up Studies
researchProduct